Combat Drugs Limited

Regd. Off: 9-109/9, Plot No.112, Road No.14, Gayatri Nagar, Bouduppal, R.R.District -500039, TS
Ph: +91-40-66200100 / 65523363 Url: www.combatdrugs.in Email: info@combatdrugs.in
CIN No.: L24230TG1986PLC006781 TIN: 36690236431 D.L.No.: TG/15/04/2016-14766

14/02/2017
To,
The General Manager
Department of Corporate Services
BSE Limited
P. J. Towers, Dalal Street,
Mumbai 400001

Sir,

Sub: Outcome of Board Meeting Approval of Quarterly Results

(Quarter ended 31st December, 2016)

Pursuant to Regulation 29 & 33 of the Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that at the
meeting of the Board of Directors of the company held today ie; 14th February, 2017, the
Statement of Un-Audited Financial Results for the quarter ended 31st December, 2016 was
approved and taken on record along with the Limited Review Report for the period issued
by the Statutory Auditors of the company.

Please find enclosed the following in respect of the above said:

1. Statement of Un-Audited Financial Results for the Quarter ended 31st Dec, 2016.
2. Limited Review Report of the Auditors on Quarterly Financial Results pursuant to the
Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015.

This is for your information and records.

Thanking You
Yours Sincerely,
For COMBAT DRUGS LIMITED

Kiran Kumar K
COMPLIANCE OFFICER
 COMBAT DRUGS LIMITED Regd.off:.9-109/9, Plot No.112, Rd No.14, Ph: 040-65523363 / 66200100
(CIN NO. CL23230TG1986PLC006781) Gayatri Nagar, Bouduppal (V), R.R.Dist URL: www.combatdrugs.in
Hyderabad ,Telangana ,500039 Mail: info@combatdrugs.in
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2016
Amount - Rs. In lakhs
Particulars
Quarter Ended 9 Months Ended Year Ended

31.12.2016 30.09.2016 31.12.2015 31.12.2016 31.12.2015 31.03.2016

Unaudited Unaudited Unaudited Unaudited Unaudited Audited
PART - I

1. Income from Operations

1 (a) Net Sales/Income from Operations (net of excise
15.31 9.85 9.91 28.23 16.84 22.30
duty)
(b) Other Operating Income 0.00 0.00 0.00 0.00 0.00 0.00
Total income from operations (net) 15.31 9.85 9.91 28.23 16.84 22.30
2 2. Expenses
a. Cost of materials consumed 12.00 5.13 2.83 19.70 8.10 11.30
b. Purchase of stock-in-trade 0.00 0.00 0.00 0.00 0.00 0.00
c. Changes in inventories of Finished goods, work-in-
0.00 0.00 0.00 0.00 0.00 0.00
progress and stock-in-trade
d. Employees benefits expense 7.02 5.09 1.53 16.19 4.59 12.38
e. Depreciation 0.00 0.00 2.85 0.00 8.56 8.56
f. Expired stocks 0.00 0.00 0.00 0.00 0.00 39.92
g. Other expenses 1.57 5.45 4.68 11.58 17.93 78.46
Total 20.59 15.67 11.89 47.47 39.18 150.62
3 Profit / (Loss) from Operations before Other
(5.28) (5.82) (1.98) (19.24) (22.34) (128.32)
Income, finance costs and Exceptional Items
4 Other Income 0.00 0.00 0.25 0.00 0.40 0.55
5 Profit / (Loss) from ordinaty activities before
(5.28) (5.82) (1.73) (19.24) (21.94) (127.77)
finance costs and Exceptional Items (3+4)
6 Finance costs 0.00 0.00 0.00 0.00 0.00 0.00
7 Profit / (Loss) from ordinary activities after
(5.28) (5.82) (1.73) (19.24) (21.94) (127.77)
finance costs but before Exceptional Items (5-6)
8 Exceptional items 0.00 0.00 0.00 0.00 28.81 0.00
9 Profit / (Loss) from Ordinary Activities before tax
(5.28) (5.82) (1.73) (19.24) (50.75) (127.77)
(7+8)
10 Tax expense 0.00 0.00 0.00 0.00 0.00 0.00
11 Net Profit / (Loss) from Ordinary Activities after tax
(5.28) (5.82) (1.73) (19.24) (50.75) (127.77)
(9+10)
12 Extraordinary Item (net of tax expenses) 0.00 0.00 0.00 0.00 0.00 0.00
13 Net Profit / (Loss) for the period (11-12) (5.28) (5.82) (1.73) (19.24) (50.75) (127.77)
14 Share of Profit / (Loss) of associates 0.00 0.00 0.00 0.00 0.00 0.00
15 Minority interest 0.00 0.00 0.00 0.00 0.00 0.00
16 Net Profit / (Loss) after taxes, minority interest
and share of profit / (loss) of associates (5.28) (5.82) (1.73) (19.24) (50.75) (127.77)
(13+14+15)
17 Paid-up equity share capital (Face value of the
800.00 800.00 800.00 800.00 800.00 800.00
Share shall be indicated) - Face value Rs. 10/-
18 Reserve excluding Revaluation Reserves as per
0.00 0.00 0.00 - 0.00 0.00
balance sheet of previous accounting year
19 i) Earnings per Share (before extraordinary items)
of Rs._____/- each (not annualised):
(a) Basic (0.07) (0.07) 0.00 (0.24) (0.06) (1.60)
(b) Diluted (0.07) (0.07) 0.00 (0.24) (0.06) (1.60)
ii) Earning per share (after extraordinary items)

(a) Basic (0.07) (0.07) 0.00 (0.24) (0.06) (1.60)

(b) Diluted (0.07) (0.07) 0.00 (0.24) (0.06) (1.60)
Notes
1.The above Financial Results as recommended by the Audit Committee were considered and approved by the Board of
Directors at their meeting held on 14th Feb, 2017.
2. The Company is operating in only one segment i.e, Pharmaceuticals and hence segment wise reporting is not made.
3. Previous year/s / period's figures have been regrouped / rearranged / recasted wherever necessary.
For and on behalf of the Board of Directors

Place: Hyderabad
Date : 14.02.2017 DIRECTOR